Vascular Biogenics Ltd expected to post a loss of 10  cents a share - Earnings Preview

Notable Labs

12/08/2022 15:34

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 15
(estimated). 
    * The Or Yehuda Israel-based   company is expected to report
 a
644.7% increase in revenue to $1.4 million from $188 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vascular Biogenics
Ltd is
for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5​, above​ its last closing price of $0.25.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.11       -0.11      -0.13     Missed  -20.4
 Dec. 31 2022  -0.08       -0.09      -0.12     Missed  -37.1
 Sep. 30 2021  -0.11       -0.11      -0.09     Beat    16.3​
 Jun. 30 2021  -0.11       -0.11      -0.12     Missed  -11.6
 ​​Mar.        -0.13       -0.13      -0.12     Beat    7.7
 31 2021                                                
 Dec. 31 2020              -0.14      -0.15     Missed  -7.1​
 Sep. 30 2020  -0.14       -0.13      -0.12     Beat    10.2
 Jun. 30 2020  -0.14       -0.14      -0.14     Met     -1.4
 This summary was machine generated August 12 at 14:34 GMT.  All
figures in US dollars  unless otherwise stated